Senolytics and Eye Health: AMD, Glaucoma, and Retinal Senescence

Evidence update: Senolytic eye-health claims are preclinical; no supplement is established to prevent or treat retinal disease.

Expert Summary

Retinal pigment epithelium cells accumulate oxidative damage from lifetime light exposure, driving senescent phenotypes by age 60–70. Senescent RPE cells produce VEGF (driving choroidal neovascularization in wet AMD), reduce photoreceptor nutrient support, and accumulate drusen-forming lipofuscin. Senolytic clearance of aged RPE cells is an active area of research.

Key Facts

As an Amazon Associate, Stacking Years earns from qualifying purchases.

Thorne Quercetin Phytosome

250 mg quercetin phytosome per capsule

Quercetin phytosome capsules.

Best for: comparing a quercetin phytosome option in Key Facts

View on Amazon · Affiliate link

Life Extension Bio-Fisetin

8 mg fisetin per capsule

Low-dose fisetin with fenugreek galactomannans.

Best for: reviewing a low-dose fisetin label in Key Facts

View on Amazon · Affiliate link

Frequently Asked Questions

Can senolytics prevent AMD?

No confirmed human evidence exists for AMD prevention by senolytics. The mechanistic rationale (RPE senescence drives AMD) is strong, and preclinical data is promising. AMD prevention trials with senolytics are a logical next step but have not been completed.

Do senolytics lower intraocular pressure in glaucoma?

No direct human evidence. Animal models show trabecular meshwork function improvement post-senolytic treatment. Human glaucoma patients considering senolytics should maintain standard treatments.

Scientific References

Retinal mechanisms are not evidence of an eye treatment

Senescence-related signaling has been studied in retinal pigment epithelium and other eye tissues, mainly in laboratory and animal models. That work helps researchers identify pathways but does not show that an over-the-counter senolytic can prevent age-related macular degeneration, glaucoma, or vision loss in people. Claims that a particular percentage of human retinal cells are senescent should be treated cautiously unless they cite a defined tissue study and patient population.

For real-world eye health, follow routine eye examinations and the treatment plan recommended by an ophthalmologist. New distortion, flashes, a curtain-like shadow, sudden vision loss, or severe eye pain needs prompt medical assessment. Do not delay anti-VEGF treatment, pressure-lowering therapy, or other indicated care to try a senolytic supplement. Research participation should be through a registered study with eye-specialist monitoring.

FAQ — Can fisetin treat AMD? No. There is no established human evidence that it treats or prevents AMD.

Research context: Review search: cellular senescence and retinal disease.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.